SARS-CoV-2 Nucleocapsid Protein Antibody (Biotin)

REQUEST MORE INFO
Catalogue No: abx243135
Price: US$333.50
(Size: 50 µl)

Click on the image to see the image legend

Available Options

* Size:


Add to Shopping Cart Buy It Now GET A QUOTE

Documents

Datasheet SDS
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Nucleocapsid Protein Antibody is a chimaeric recombinant antibody conjugated to Biotin for the detection of SARS-CoV-2/COVID-19 NP. This antibody is expressed in HEK293 cells and contains Mouse scFv and C-terminal Human IgG1 Fc tag.

The SARS-CoV-2 Nucleoprotein (also known as Nucleocapsid Protein or N Protein) is a protein that binds to the RNA in the viral particle. Changes to two amino acids in the nucleoprotein are thought to contribute to the virus’ ability to infect humans; this mutation allows the virus to reduce the binding capability of an HLA-C allele found in many Europeans. The nucleoprotein is the second most-common protein in SARS-CoV-2 targeted by the immune system, after the spike protein.

Target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein
Clonality Monoclonal
Reactivity Virus
Origin Human
Expression Recombinant
Tested Applications ELISA
Host Human, Mouse
Recommended dilutions Optimal dilutions/concentrations should be determined by the end user.
Conjugation Biotin
Immunogen abx600062 - Recombinant SARS-CoV-2 Nucleoprotein (1-419 AA) expressed in Mammalian cells
Isotype IgG1
Form Liquid
Purification Purified by affinity chromatography.
Storage Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC P0DTC9 (UniProt, ExPASy)
GeneID 43740575
Buffer 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% glycerol.
Availability Shipped within 5-10 working days.
Note THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Research Articles on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid Protein


Write a review